慢性粒单核细胞白血病合并自身免疫性疾病研究进展  

Research advances of chronic myelomonocytic leukemia with autoimmune diseases

作　　者：查蔷 李建勇[1] 沈文怡[1] ZHA Qiang;LI Jianyong;SHEN Wenyi(Department of Hematology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院血液科,江苏南京210029

出　　处：《南京医科大学学报（自然科学版）》2024年第3期417-422,共6页Journal of Nanjing Medical University(Natural Sciences)

基　　金：国家自然科学基金(81400079);江苏省卫生厅科研项目(Z201402);江苏省六大人才高峰(WSN⁃026)。

摘　　要：慢性粒单核细胞白血病(chronic myelomonocytic leukemia,CMML)是一类以外周血单核细胞增多及骨髓异常增生为特征的克隆性造血干细胞疾病。CMML患者常合并自身免疫性疾病(autoimmune disease,AID),AID与CMML合并发生的机制尚不明确,给此类患者治疗的选择带来了一定挑战。已有研究提示合并AID对CMML患者的预后及治疗具有重要意义,本文就CMML患者合并AID的类型、可能发病机制、预后及相关治疗进展进行文献复习及综述。Chronic myelomonocytic leukemia(CMML)is a clonal hematopoietic stem cell disorder characterized by peripheral blood monocytosis and myelodysplasia.Patients with CMML often present with concomitant autoimmune diseases(AID).However,the relationship between the pathogenesis of AID and CMML remains unclear,posing challenges for treatment selection.Several studies have suggested that the prognosis and treatment strategy in CMML patients with concurrent AID is of great significance.This article provides a comprehensive review of the literature on the types,possible mechanisms,prognosis,and relevant treatment progress of concomitant AID in CMML patients.

关 键 词：慢性粒单核细胞白血病 自身免疫性疾病 发病机制 治疗 预后 

分 类 号：R733.72[医药卫生—肿瘤]